Cancer Immunotherapy, Part 1: Current Strategies and Agents.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.Frontiers in medicine · 2020
   Pooled it
2. A2AR as a key target for immune microenvironment remodeling in prostate cancer.Translational oncology · 2026
   Article
3. Tumor-embedded Immunity and TRM Cell Functions in Cancer.Mini reviews in medicinal chemistry · 2026
   Review
4. Predicted IL-18/IL-18R Binding Improvement Through Protein Interface Modification with Computer-Aided Design.Biomolecules · 2025
   Article
5. Molecular Docking, Molecular Dynamics Simulation, and Pharmacophore-Based Virtual Screening Unveil Natural Compounds with TIM-3 Inhibitory Activity.Journal of pharmacy & bioallied sciences · 2025
   Article
6. Immunotherapy in gastrointestinal cancers: current strategies and future directions - a literature review.Annals of medicine and surgery (2012) · 2025
   Review
7. A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia.Frontiers in immunology · 2025
   Review
8. Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.Frontiers in immunology · 2025
   Article
9. The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer.Current cancer drug targets · 2025
   Review
10. A Review of Novel Cancer Therapeutics and Current Research Trends.TheScientificWorldJournal · 2025
    Review
11. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024
    Review
12. Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024
    Review
13. Mitochondrial VDAC1 Silencing in Urethane-Induced Lung Cancer Inhibits Tumor Growth and Alters Cancer Oncogenic Properties.Cancers · 2024
    Article
14. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.Nature reviews. Clinical oncology · 2024
    Review
15. Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.Advanced healthcare materials · 2024
    Review
16. Mutations in Mismatch Repair Genes and Microsatellite Instability Status in Pancreatic Cancer.Cancers · 2024
    Article
17. Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?Cancers · 2024
    Review
18. Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.BMC complementary medicine and therapies · 2023
    Article
19. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.Cell reports. Medicine · 2023
    Review
20. Molecules (Basel, Switzerland) · 2023
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract